Viking Therapeutics reports positive topline results from maintenance study of GLP-1/GIP agonist VK2735; shares jump 39% pre-market

Viking Therapeutics announced positive topline results from a maintenance study of its GLP-1/GIP agonist VK2735, reporting 22% placebo-adjusted weight loss at week 33 with weekly 17.5 mg dosing. The stock rose about 39% in pre-market trading.

Detected & updated continuously · Source: Nebula